Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y<sub>12</sub>receptors<i>in vitro</i>
Heather M. Judge(Royal Hallamshire Hospital), Robert F. Storey(University of Sheffield), Robert Buckland(Umeå University), Joseph A. Jakubowski(Indiana Biosciences Research Institute)
Cited by 39
Related Papers
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
|European Heart Journal|2011|3.5k
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
|New England Journal of Medicine|2015|2k
Complete Revascularization with Multivessel PCI for Myocardial Infarction
|New England Journal of Medicine|2019|926